Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
复制标题
DOI：
10.1111/j.1559-4572.2008.07552.x
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Shannon, Richard P
中科院分区：
文献类型：
--
作者：
Dorey-Stein, Zachariah;Amorosa, Valerianna K;Shannon, Richard P
The introduction of highly active antiretroviral therapy (HAART) has led to reductions in morbidity associated with opportunistic infections and has significantly decreased mortality among patients living with human immunodeficiency virus (HIV) infection [1]. However, the emergence of long-term drug-related adverse effects has become a major concern to patients with HIV, and a challenge to HIV practitioners. A variety of treatment-related metabolic changes have been observed since the introduction of HAART, including dyslipidemia, insulin resistance, and diabetes mellitus [2]. In addition, changes in body fat distribution, often referred to as “lipodystrophy,” have also been recognized [3] and can have deleterious effects on HIV-infected patients’ quality of life [4, 5]. Collectively, these metabolic changes may place HIV-infected patients at increased risk for developing cardiovascular disease. In this report, we describe a case of HIV-associated lipodystrophy accompanied by dramatic weight gain, dyslipidemia, and obstructive sleep apnea following initiation of HAART.
